# reload+after+2024-01-22 05:45:07.371310
address1§5959 Horton Street
address2§Suite 300
city§EmeryVille
state§CA
zip§94608
country§United States
phone§510 871 6100
fax§510 597 1488
website§https://gritstonebio.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, a neoantigen-based immunotherapy, which is in Phase 2/3 clinical trials for the treatment of solid tumors, including microsatellite stable colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
fullTimeEmployees§233
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.', 'age': 56, 'title': 'Co-Founder, President, CEO & Director', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 983440, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Erin E. Jones M.S.', 'age': 51, 'title': 'Executive VP & COO', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 658012, 'exercisedValue': 0, 'unexercisedValue': 128794}, {'maxAge': 1, 'name': 'Dr. Karin  Jooss Ph.D.', 'age': 58, 'title': 'Executive VP and Head of Research & Development', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 706071, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Vassiliki  Economides', 'age': 42, 'title': 'Executive VP & CFO', 'yearBorn': 1981, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. James  Cho', 'title': 'Chief Accounting Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'George  MacDougall', 'title': 'Director of Investor Relations & Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Stacy  Proctor', 'title': 'Executive VP & Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Matthew J. Hawryluk M.B.A., Ph.D.', 'age': 45, 'title': 'Executive VP & Chief Business Officer', 'yearBorn': 1978, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Vijay  Yabannavar Ph.D.', 'age': 61, 'title': 'Executive VP & Chief Technical Development Officer', 'yearBorn': 1962, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§7
boardRisk§2
compensationRisk§9
shareHolderRightsRisk§8
overallRisk§7
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.274
priceToSalesTrailing12Months§18.27942
currency§USD
dateShortInterest§1702598400
forwardEps§-1.1
exchange§NMS
quoteType§EQUITY
shortName§Gritstone bio, Inc.
longName§Gritstone bio, Inc.
firstTradeDateEpochUtc§1538141400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§7309a12e-e7eb-310b-86a1-d3f02f2f34ec
gmtOffSetMilliseconds§-18000000
targetHighPrice§20.0
targetLowPrice§6.0
targetMeanPrice§10.0
targetMedianPrice§7.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§3.605
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
